Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study.

Thorac Cancer · 2023 · PMC9968599 · PMID 36627112

Europe PMC DOI

hedged sentence

0.7500

closest p · 15.0× alpha

0.7500

boldest claim

The sentences

did not reach statistical significancep = 0.75not close (p > 0.1)

PFS was also shorter but did not reach statistical significance (15.4 vs. 20.3 months, HR 0.92, 95% CI 0.54–1.55, log rank p = 0.75; Figure S2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.